SUNPHARMA

will take a disciplined M&A approach, focusing on deals that strengthen long-term strategy while prioritising organic growth. Chairman Dilip Shanghvi said the company is cautiously evaluating biosimilars and emerging markets, with North America key for innovation, stressing financial prudence and repayment ability in acquisitions.